Ilene Galinsky Highlights Evolution of AML Treatment
Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner, at Dana Farber Cancer Institute, discusses how treatment for patients with acute myeloid leukemia has evolved in recent years.
Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner, at Dana Farber Cancer Institute, discusses how treatment for patients with acute myeloid leukemia (AML) has evolved in recent years.
It is a very exciting to be a nurse or nurse practitioner in oncology, Galinksy explained, especially with the advances in therapeutics for patients with AML. These novel therapies are now less toxic compared with 7+3 chemotherapy, which patients would previously receive regardless of their molecular makeup.
The evolution in science has also led to identification of molecular abnormalities and ways to target these aberrations through treatment, Galinsky explains. These precision medicine approaches have led to improvements in overall survival as well as quality of life, she concludes.
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
May 8th 2024Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.
Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma
May 6th 2024Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.
